ZURICH - Novartis Chief Executive, Joe Jimenez, told a Swiss newspaper that the first human tests of a contact lens it is developing with Google for diabetic patients will be conducted in 2016.
(Reuters Health) - Intimate partner violence or abuse can take the form of birth control sabotage, pregnancy pressure or coercion, which can have devastating consequences including unintended pregnancy, abortion and psychological trauma, according to a new review.
NEW YORK (Reuters Health) - Educating athletes about the risk of concussion may do little to change long-term behavior, a new qualitative research review has found.
(Reuters Health) - Weight-loss surgery beats medication for controlling type 2 diabetes in obese people, according to the longest-term trial ever to compare the two approaches.
CHICAGO - Cases of Legionnaires' disease have been increasing dramatically in the United States, with reported cases in August alone more than doubling from expected levels for that period, U.S. health officials say.
ZURICH - Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma that the company said gives new options for adult patients whose disease has progressed following standard therapy.
BERLIN - Philips Electronics will emerge from its radical transition away from the lighting industry as a more profitable company focused on consumer healthcare, the head of the group's Personal Health business told Reuters.
LONDON/MUMBAI - A major Indian supplier of tuberculosis drugs to developing countries has been severely criticized by the World Health Organization for inadequate manufacturing standards and poor testing procedures.
(Reuters Health) - A study of people with rheumatoid arthritis (RA) finds that those in wealthy nations are more troubled by it, even though people in poor countries have more severe symptoms.
- Alexion Pharmaceuticals Inc said the U.S. Food and Drug Administration would delay by three months its decision on approving a key drug the company got through the acquisition of Synageva BioPharma Corp.